Please assess the completion status of the following clinical trial:

Trial Title: Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the colon or rectum~* Stage IV~* Existence of two-dimensional measurable disease. The measurable disease should not have been irradiated.~* Absence or irradiated and stable central nervous system metastatic disease.~* Life expectancy of more than 3 months.~* Age ≥ 70 years.~* Performance status (WHO) ≤ 2.~* Adequate bone marrow function (Absolute neutrophil count \>1000/mm3, Platelet count \>100000/mm3, Hemoglobin \>9gr/mm3).~* Adequate liver (Bilirubin \<1.5 times upper limit of normal and SGOT/SGPT \<2 times upper limit of normal).~* Creatinine clearance (Cockcroft-Gault formula) \>30ml/min.~* No other invasive malignancy within the past 5 years except nonmelanoma skin cancer.~* Presence of a reliable care giver.~* Informed consent.~Exclusion Criteria:~* Prior chemotherapy for metastatic disease.~* History of thromboembolic disease or myocardial infraction within the last 6 months.~* Peripheral neuropathy ≥ grade 2.~* Bowel obstruction or chronic diarrhea.~* Psychiatric illness or social situation that would preclude study compliance.~* Other concurrent uncontrolled illness.~* Other concurrent investigational agents.

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- XELOX/Avastin (Type: EXPERIMENTAL): Capecitabine Oxaliplatin Bevacizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).